Across studies, consistencies are striking: (i) CAF interventions that increase functional m6A in cancer cells tend to enhance invasiveness, metabolic plasticity, ferroptosis resistance, and, indirectly, immune evasion; (ii) exosomal delivery of METTL3 is sufficient to rewire tumor metabolism and growth; and (iii) targeted disruption of these stromal–epitranscriptomic nodes restrains tumor progression in vivo. The gene discussed is METTL3; the disease is cancer.